Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.33 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8070978 | 0.98 | SPHK2 (0.38) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL1937656 | 0.98 | SPHK2 (0.42) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL4465867 | 0.98 | SPHK2 (0.42) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL1937313 | 0.98 | SPHK2 (0.42) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL1938682 | 0.98 | SPHK2 (0.42) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL1937984 | 0.98 | SPHK2 (0.42) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL20361795 | 0.94 | GRIN2D (0.37) | SPHK2SPHK1NOS3NOS1NOS2 | |
| SCHEMBL9235649 | 0.87 | — | — | |
| SCHEMBL1505132 | 0.87 | — | — | |
| SCHEMBL19371464 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539099-A4 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | LYOTROPIC THERAPEUTICS LLC (US) | 2009-03-18 | — | — | EP | claimed |
| EP-1539099-A2 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | Lyotropic Therapeutics, LLC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040022820-A1 | Reversed liquid crystalline phases with non-paraffin hydrophobes | LYOTROPIC THERAPEUTICS, INC. | 2004-02-05 | — | — | US | claimed |
| WO-2003106382-A2 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | LYOTROPIC THERAPEUTICS, INC. (US) | 2003-12-24 | — | — | WO | claimed |
| US-20020102280-A1 | Solvent systems for pharmaceutical agents | LYOTROPIC THERAPEUTICS, INC. | 2002-08-01 | — | — | US | claimed |
| EP-3230274-B1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-10023539-B2 | Aryl-cyanoguanidine compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| EP-3283480-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283478-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-02-21 | — | — | EP | disclosed |
| EP-3230274-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-18 | — | — | EP | disclosed |
| CN-107207442-A | Novel aryl-cyanoguanidine compounds | 拜耳医药股份有限公司 | 2017-09-26 | — | — | CN | disclosed |
| WO-2016166186-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | WO | disclosed |
| US-4265905-A | FOR AUTOIMMUNE DISEASES | MERCK & CO., INC. (US) | 1981-05-05 | — | — | US | disclosed |
| US-4265905-A | FOR AUTOIMMUNE DISEASES | MERCK & CO., INC. (US) | 1981-05-05 | — | — | US | disclosed |
| US-4202903-A | Acyl cyanoguanidines for treating rheumatoid arthritis | MERCK & CO., INC. (US) | 1980-05-13 | — | — | US | disclosed |
| US-4202903-A | Acyl cyanoguanidines for treating rheumatoid arthritis | MERCK & CO., INC. (US) | 1980-05-13 | — | — | US | disclosed |
| US-4202903-A | Acyl cyanoguanidines for treating rheumatoid arthritis | MERCK & CO., INC. (US) | 1980-05-13 | — | — | US | disclosed |
| US-4057642-A | ANTIINFLAMMATORY, RHEUMATOID ARTHRITIS | MERCK & CO., INC. (US) | 1977-11-08 | — | — | US | disclosed |
| US-4057642-A | ANTIINFLAMMATORY, RHEUMATOID ARTHRITIS | MERCK & CO., INC. (US) | 1977-11-08 | — | — | US | disclosed |
| US-4057642-A | ANTIINFLAMMATORY, RHEUMATOID ARTHRITIS | MERCK & CO., INC. (US) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023539-B2 | Aryl-cyanoguanidine compounds | SMYD2, SETD2, SMYD3 | SPHK2 620/4885SPHK1 918/4885DNM1 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.